Primus In News
CDMOs gear up for peptide gold in weightloss race
20-07-2025
Nilaya Varma, Group CEO, Primus Partners, shares his view on India’s emerging position in the peptide drug manufacturing space. He highlights that while India is well-placed to tap into the growing global demand—especially with upcoming patent expiries like that of semaglutide—peptide manufacturing continues to face challenges. These include the availability of protected amino acids, coupling reagents, and the need for advanced purification processes for bulk APIs. Despite this, he notes the sector’s strong growth potential, backed by sustained investments in technology and capacity.
Explore Related Insights
- Budget 2023: Start-ups hail extension of tax holiday, loss carry forward period
- AI drives funding boom for cybersecurity startups in India
- Design in India, Design for the World: What India's gaming industry needs to become a global leader
- India's AI ambitions: Are we really falling behind the U.S. and China, or i the picture more complex?
